Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.
Iván Márquez Rodas, MD, PhD
Advertisement
Articles by Iván Márquez Rodas, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5